Searched for
BROKERAGE REVENUE
Nithin Kamath warns closing auction session may hit Zerodha’s revenue from August 3Zerodha CEO Nithin Kamath said the new Closing Auction Session for F&O stocks could reduce brokerage revenue by 1–5% while making market ti...- Meesho shares can rally to Rs 240? Why Motilal Oswal initiated coverage on the platform stockMotilal Oswal has begun coverage on Meesho, awarding it a buy rating along with a target price indicating strong potential. The brokerage b...
- FIIs triple stake in Sterlite Tech after a stellar 400% surge this year. More legs to the rally?Sterlite Technologies has surged over 400% in 2026, while FIIs nearly tripled their stake to 19.7% as of July 2026. The stock gained invest...
- Tata Power shares get Equal Weight rating from Morgan Stanley with target price of Rs 399Tata Power shares traded lower despite Wall Street brokerage Morgan Stanley retaining its "Equal Weight" rating and Rs 399 target price fol...
- Bharat Electronics shares fall over 3% after Q1 results. Here's what Nomura, Motilal Oswal and other brokerages sayBharat Electronics (BEL) shares fell 3.5% after the defence PSU reported mixed Q1FY27 results, with profit rising 9% year-on-year but decli...
- Coal India shares fall 2% after Q1 results. What are Jefferies, other brokerages saying?Coal India shares fell after the state-run miner reported a marginal 1% year-on-year rise in Q1 FY27 consolidated net profit to Rs 8,852 cr...
- Dr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?Dr Lal PathLabs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomu...
- Buy, Sell or Hold: Anand Rathi maintains buy on Bansal Wire; Equirus Securities recommends buy on Greenply IndustriesAnand Rathi and Equirus Securities remain bullish on select stocks with strong earnings visibility. Anand Rathi maintained a 'Buy' on Bansa...
- Indo-MIM IPO Day 3: GMP signals 39% listing gain, issue subscribed over 3x. What are brokerages saying?Indo-MIM IPO GMP: Indo-MIM's Rs 3,811 crore IPO is in its final bidding day with robust demand. The IPO has been subscribed 3.07 times by t...
- Tata Consumer shares jump 3% after Q1 results. Here’s why Nomura, Motilal see strong upside potentialTata Consumer Products shares rose 3% after the FMCG major reported a 27.8% YoY jump in Q1 FY27 net profit to Rs 427 crore, while revenue i...
- SBI Funds Management shares fall below IPO price, but brokerages remain bullish. Time to buy?SBI Funds Management shares slipped below their IPO price after listing, but brokerages remain bullish on the stock, citing strong parentag...
- Forget selling! FIIs doubled down on this AI multibagger stock that's up 200% YTDHFCL has emerged as a favourite among foreign investors, with FIIs more than doubling their stake to 15.7% in Q1 despite the stock surging ...
- IndiGo shares sink 3% after Rs 238 crore Q1 loss, but why are Citi and Nuvama raising target prices?InterGlobe Aviation (IndiGo) reported a Q1FY27 net loss of Rs 238 crore as soaring fuel costs pushed expenses ahead of revenue growth. Desp...
- Meesho cracks 5% as weak Q2 outlook spooks Street; Citi, Morgan Stanley reactMeesho shares fell after the company warned of slower NMV growth in the September quarter due to the rescheduling of its flagship festive s...
- Infosys shares fall 3% as JPMorgan downgrades stock, Jefferies cuts target after Q1 resultsInfosys shares fell after global brokerages turned cautious following the company's Q1 FY27 results and a cut to the upper end of its reven...
- Buy, Sell or Hold? Goldman Sachs maintains a buy on Eternal; Citi recommends sell rating on Dr Reddy’s Laboratories post Q1 resultsGoldman Sachs and Citi have issued fresh post-Q1 calls on three stocks. Goldman stays bullish on Eternal (Buy, target Rs 345, 21% upside) d...
- Infosys Q1 preview: Guidance cut expected? Infosys may not have good news for investors in Q1 resultsInfosys is expected to post double-digit growth in revenue and profit for Q1FY27, aided by seasonal factors and acquisitions. However, brok...
- MedPlus Health shares tumble 16% after Q1 profit falls 21% YoY. Should you buy, sell or hold?MedPlus Health Services shares tumbled after the company reported a weaker-than-expected Q1FY27. Despite healthy 21.9% revenue growth to ₹1...
- IT growth under pressure amid delayed deal ramp-upsRatings agency Crisil last week forecasted the $315-billion industry to grow just 1-3% on a constant currency basis in FY27 and 2-4% in FY2...
- Goldman Sachs initiates coverage on Sansera Engineering, 3 other auto ancillary stocks with upside of up to 28%. Here’s whyGoldman Sachs has initiated coverage on four Indian auto ancillary companies, turning bullish on Sansera Engineering and Craftsman Automati...
Load More
